Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

CytomX Therapeutics Inc

Healthcare US CTMX

3.22USD
0.06(1.90%)

Last update at 2026-06-03T20:24:00Z

Day Range

3.173.31
LowHigh

52 Week Range

0.628.21
LowHigh

Fundamentals

  • Previous Close 3.16
  • Market Cap1057.11M
  • Volume3531181
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-18.18800M
  • Revenue TTM76.20M
  • Revenue Per Share TTM0.55
  • Gross Profit TTM 76.20M
  • Diluted EPS TTM-0.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -17.13000M 32.09M 3.32M -99.31700M -83.60900M
Minority interest - - - - -
Net income -17.36800M 31.87M -0.56900M -97.29900M -80.64800M
Selling general administrative 29.84M 29.73M 30.02M 42.85M 39.16M
Selling and marketing expenses - - 0.15M - -
Gross profit 76.20M 138.10M 101.21M 53.16M 69.57M
Reconciled depreciation 1.38M 1.77M 2.30M 2.44M 2.71M
Ebit -19.56400M 25.00M -6.48400M -103.77800M -86.48700M
Ebitda -18.18800M 26.76M -4.30900M -101.33500M -83.78100M
Depreciation and amortization 1.38M 1.77M 2.17M 2.44M 2.71M
Non operating income net other - - - 0.17M 0.17M
Operating income -19.56400M 25.00M -6.48400M -101.33500M -83.78100M
Other operating expenses 95.77M 113.11M 107.70M 154.50M 153.35M
Interest expense - - - -2.01800M 0.17M
Tax provision 0.24M 0.22M 2.82M 0.00000M 0.00000M
Interest income 5.21M 7.14M 8.07M 1.68M 0.26M
Net interest income 5.21M 7.14M 8.07M 1.68M 0.26M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.24M 0.22M 3.89M -2.01800M -2.96100M
Total revenue 76.20M 138.10M 101.21M 53.16M 69.57M
Total operating expenses 95.77M 113.11M 107.70M 154.50M 153.35M
Cost of revenue - 1.77M 2.17M - -
Total other income expense net 2.43M 7.10M 9.81M 2.02M 0.17M
Discontinued operations - - - - -
Net income from continuing ops -17.36800M 31.87M -10.18100M -115.87000M -83.60900M
Net income applicable to common shares - - - -115.87000M -83.60900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 151.57M 120.53M 205.15M 260.89M 339.41M
Intangible assets 0.44M 0.58M 0.73M 0.88M 1.02M
Earning assets - - - - -
Other current assets 4.86M 3.58M 5.00M 7.47M 4.29M
Total liab 52.56M 120.99M 252.60M 346.64M 250.03M
Total stockholder equity 99.01M -0.45600M -47.44700M -85.75100M 89.38M
Deferred long term liab - - - - -
Other current liab 14.20M 12.34M 17.60M 24.45M 30.62M
Common stock 0.00200M 0.00100M 0.00100M 0.00100M 0.00100M
Capital stock 0.00200M 0.00100M 0.00100M 0.00100M 0.00100M
Retained earnings -711.94900M -691.57900M -723.44800M -722.87900M -533.72400M
Other liab - - - 180.06M 125.66M
Good will 0.95M 0.95M 0.95M 0.95M 0.95M
Other assets - - - 0.94M 1.82M
Cash 12.67M 38.05M 17.17M 193.65M 205.53M
Cash and equivalents - - - - -
Total current liabilities 46.62M 85.77M 155.91M 152.61M 106.32M
Current deferred revenue 26.88M 67.20M 132.27M 121.27M 69.26M
Net debt -8.42700M -28.66700M -3.19700M -175.59300M -187.47400M
Short term debt 4.24M 5.14M 4.59M 4.08M 3.62M
Short long term debt - - - - -
Short long term debt total 4.24M 9.38M 13.97M 18.06M 18.06M
Other stockholder equity 810.84M 691.10M 675.90M 637.12M 623.34M
Property plant equipment - - - 5.96M 5.96M
Total current assets 143.92M 107.31M 182.94M 237.10M 310.30M
Long term investments - - - - -
Net tangible assets - - - -2.42900M 87.41M
Short term investments 124.39M 62.57M 157.34M 99.70M 99.70M
Net receivables 2.01M 3.10M 3.43M 35.99M 0.79M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.30M 1.09M 1.46M 2.81M 2.82M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.11M 0.03M 0.10M 0.01000M -0.24200M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00100M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -623.56200M -533.72400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.56M 1.09M 0.08M 0.94M 1.82M
Deferred long term asset charges - - - - -
Non current assets total 7.64M 13.23M 22.21M 23.79M 29.11M
Capital lease obligations 4.24M 9.38M 13.97M 18.06M 21.67M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -59.52400M 99.70M -63.72200M 24.10M 24.10M
Change to liabilities - - - -0.13900M -0.13900M
Total cashflows from investing activities -59.74400M 99.70M -150.67400M 22.49M 22.49M
Net borrowings - - - - -
Total cash from financing activities 110.45M 7.52M 30.23M 0.65M 110.21M
Change to operating activities - - - -12.09100M 11.64M
Net income -20.37000M 31.87M -0.56900M -99.31700M -83.60900M
Change in cash -24.88500M 20.99M -176.47900M -11.88000M 13.67M
Begin period cash flow 39.08M 18.09M 193.65M 206.45M 192.78M
End period cash flow 14.19M 39.08M 17.17M 194.57M 206.45M
Total cash from operating activities -75.58700M -86.23100M -56.03500M -110.78800M -119.03100M
Issuance of capital stock 109.64M 6.91M - 0.00000M 107.71M
Depreciation 0.15M 1.77M 2.17M 2.44M 2.71M
Other cashflows from investing activities - - - - -
Dividends paid 3.00M - - - -
Change to inventory - - - - 11.64M
Change to account receivables 1.09M 0.33M 32.55M -35.19600M 0.00800M
Sale purchase of stock - - - 110.21M 110.21M
Other cashflows from financing activities 3.00M 0.61M 30.23M 98.26M 2.50M
Change to netincome - - - 13.17M 13.17M
Capital expenditures 0.22M 0.31M 0.84M 1.74M 1.61M
Change receivables - - - 0.00800M 0.00800M
Cash flows other operating - - - -19.17500M -57.70200M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 13.67M 13.67M
Change in working capital -68.57600M -126.41500M -62.50900M -30.65400M -54.70000M
Stock based compensation 6.30M 7.67M 8.56M 13.12M 13.17M
Other non cash items 6.91M -1.12100M -3.69000M 3.62M 3.13M
Free cash flow -75.80700M -86.54100M -56.87500M -112.52800M -120.64000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CTMX
CytomX Therapeutics Inc		 0.06 1.90% 3.22 - 14.20 13.50 10.39 11.76 24.67
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

CytomX Therapeutics Inc

151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Sean A. McCarthy D.Phil., DPHIL Chairman & CEO 1967
Mr. Lloyd A. Rowland Jr., J.D. Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec. 1957
Mr. Christopher W. Ogden Sr. VP of Fin. and Accounting, Principal Financial Officer & Principal Accounting Officer 1984
Dr. Chau Cheng M.B.A., Ph.D. VP of Investor Relations & Corp. Communications NA
Ms. Danielle Olander-Moghadassian Sr. VP & Chief HR Officer NA
Ms. Leslie Robbins Sr. VP of Intellectual Property NA
Dr. Marcia P. Belvin Ph.D. Sr. VP & Head of Research NA
Mr. Jeffrey Landau B.S., M.B.A. Sr. VP, Head of Strategy & Chief Bus. Officer 1978
Dr. Jamie Moore Ph.D. Sr. VP & Head of Protein and Process Sciences and Manufacturing NA
Dr. Hoyoung Huh M.D., Ph.D. Special Advisor to Chief Exec. Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.